

Ubamatamab

Cat. No.:	HY-P99539
CAS No.:	2305629-50-7
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity ^[1] .	
In Vitro	Ubamatamab (REGN4018; 0.1 pM-10 nM; 48 hours) induces human T cells and cynomolgus T cells to kill OVCAR-3 cells (EC50, 13.6 pM and 30.6 pM, respectively) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	OVCAR-3 cells
	Concentration:	0.1 pM-10 nM
	Incubation Time:	48 hours
	Result:	Induced human T cells and cynomolgus T cells to kill OVCAR-3 cells.
	In Vivo	Ubamatamab (REGN4018; 0.01-0.5 mg/kg; i.p; on days 6, 10, 13, 16, and 21) potently inhibits growth of intraperitoneal ovarian tumors ^[1] . Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:		NOD SCID gamma (NSG) mice injected with OVCAR-3/Luc cells ^[1]
Dosage:		0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg
Administration:		i.p; on days 6, 10, 13, 16, and 21
Result:		Significantly reduced tumor burden, and did not result in any changes in weight.
Animal Model:		Cynomolgus monkeys
Dosage:		0.01, 0.1, or 1 mg/kg

Administration:	i.p; once a week; total of five doses
Result:	Showed minimal and transient increases in serum cytokines and C-reactive protein.

REFERENCES

[1]. Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA